FeesSafety
Pluang+
Home/News Feed/Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.
NVS
$157.00
+$0.92 +0.59%

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.

Company Fundamentals
21 Jul 2026, 05:00 WIB
Gordon Thompson
View Source
Neutral
Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.

Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 billion. Investors are closely watching upcoming drug trial results later this year, which are crucial for supporting Novartis' premium valuation, reflected in its P/E ratio of 21.30. Financial health metrics like a Debt-to-Equity ratio of 1.22 and a Current Ratio of 0.85 provide insight into the company's stability ahead of the earnings release on July 21, 2026.

More News (NVS)

Monte Rosa hits $37.5M milestone as Novartis starts Phase 2 trial for arthritis drug MRT-6160

Monte Rosa hits $37.5M milestone as Novartis starts Phase 2 trial for arthritis drug MRT-6160

Monte Rosa Therapeutics announced that Novartis has initiated a second Phase 2 clinical trial for MRT-6160 (DDY391), targeting moderate to severe psoriatic arthritis. This follows a prior Phase 2 trial in Sjögren's disease and triggers a $37.5 millio...

Company Fundamentals
Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App